Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab and short prednisone taper in giant cell arteritis
NCT03726749Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2018
- Primary completion
- Dec 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab in giant cell arteritis (GCA), sponsored by Massachusetts General Hospital. Started Nov 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03726749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726749.